BioVersys Issues Invitation to its 2026 Annual General Meeting of Shareholders 07.04.2026, 07:00 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
BioVersys 28,90 CHF -0,34 % SIX Swiss (CHF)

BioVersys AG / Key word(s): AGMEGM
BioVersys Issues Invitation to its 2026 Annual General Meeting of Shareholders

07-Apr-2026 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


 

Basel, Switzerland. (April 7, 2026), 7.00am CEST. Ad hoc announcement pursuant to Art. 53 LR.

 

BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria, has issued the invitation to its upcoming Annual General Meeting (AGM) of shareholders.

 

The AGM will be held on Thursday, April 30th, 2026 at 12.00 pm CEST at ZIP Auditorium Stückipark, Hochbergerstrasse 60F, 4057 Basel, Switzerland.

 

Agenda for the AGM 2026

  1.      Annual Report 2025 (Annual Financial Statements and Consolidated Financial Statements 2025; Auditor’s Report)
  2.      Discharge of the Members of the Board of Directors and the Executive Committee from Liability
  3.      Appropriation of Financial Result 2025
  4.      Elections and / or Re-elections
    1.      Election / Re-election of the Chairman and the Members of the Board of Directors
    2.      Re-election of the Members of the Compensation and Nomination Committee
    3.      Re-election of the Independent Voting Rights Representative
    4.      Election of the Auditors
  5.      Approval of the Compensation of the Board of Directors and the Executive Committee
    1.      Approval of the Compensation of the Board of Directors
    2.      Approval of the Compensation of the Executive Committee

 

Dr. William Jenkins will not stand for re-election. The Board of Directors and Management thank Dr. Jenkins for his invaluable contributions to the Board of Directors of BioVersys and wish him all the best going forward. The Board of Directors proposes to elect Ms. Simona Skerjanec as a new member of the Board of Directors. Ms. Skerjanec brings extensive international pharmaceutical leadership in developing and commercializing innovative therapies and her expertise will be a valuable addition to the BioVersys Board of Directors as the Company matures its pipeline.

 

Notes to Shareholders

The invitation, including the agenda and the proposals of the Board of Directors, will be distributed to shareholders by post. In order to participate and vote at the AGM, shareholders must be registered in the company’s shareholder register by April 17, 2026, at the latest.

 

The Annual Report (including the Auditors’ reports) and the Invitation to the AGM are available on the Company’s website under the following links:

Annual Report: https://ir.bioversys.com/investor-relations/financials/financial-reports

Invitation AGM: https://ir.bioversys.com/investor-relations/governance-csr/annual-general-meeting

 

 

About BioVersys

BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3), and tuberculosis (alpibectir, Phase 2, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland.

BioVersys contacts  

Anca Cighi, Head of IR and Communications, Tel. + 41 79 949 33 09; E-mail: Anca.Cighi@bioversys.com

For Investors: IR@bioversys.com

www.bioversys.com

 

 

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning BioVersys and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioVersys to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioVersys is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

 

 



End of Inside Information

2303842  07-Apr-2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer